文献速递乳腺癌

新辅助乳腺癌临床试验疗效终点的标准化定义:NeoSTEEP

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
PubMed 文献 · J Clin Oncol · 2023-07-11

NeoSTEEP多学科专家工作组旨在为neoadjuvant乳腺癌临床试验的疗效终点提供标准化定义。工作组推荐病理完全缓解(pCR)的首选定义为完整切除的乳腺标本及所有采样区域淋巴结中无残留浸润性癌(ypT0/Tis ypN0),残余肿瘤负荷应作为次要终点,激素受体阳性疾病需要替代终点,并强调事件发生时间终点的测量起点及活检、影像和病理淋巴结评估的标准化。

要点

  • 推荐pCR首选定义为切除乳腺标本及所有采样区域淋巴结无残留浸润性癌(ypT0/Tis ypN0)。
  • 残余肿瘤负荷应作为次要终点,激素受体阳性疾病需要替代终点。
  • 事件发生时间终点应关注测量起点,试验应包含从随机分组开始的终点以捕获术前进展和死亡事件。

核心结论

  • 除pCR外的终点应根据肿瘤的临床和生物学特征及所研究治疗药物选择。
  • 一致的预设定义和干预对于有临床意义的试验结果和跨试验比较至关重要。

研究设计与样本

  • NeoSTEEP多学科专家工作组由专家组成,聚焦于新辅助全身治疗临床试验的疗效终点,包括病理终点和事件发生时间生存终点,尤其针对注册意图。
  • 工作组考虑了亚型和治疗方法、影像学、手术时淋巴结分期、双侧和多灶性疾病、相关性组织采集以及美国食品药品监督管理局监管考虑等特殊问题。

主要发现

  • 工作组推荐pCR的首选定义为完整切除的乳腺标本和所有采样区域淋巴结中无残留浸润性癌(根据AJCC分期为ypT0/Tis ypN0)。
  • 残余肿瘤负荷应作为次要终点,以促进未来对其效用的评估。
  • 激素受体阳性疾病需要替代终点。
  • 事件发生时间生存终点定义应特别关注测量起始点。
  • 试验应包含起源于随机分组的终点(无事件生存和总生存),以捕获术前进展和死亡作为事件。

关键数值与推荐

  • pCR首选定义:完整切除的乳腺标本和所有采样区域淋巴结中无残留浸润性癌(ypT0/Tis ypN0 per AJCC staging)。
  • 残余肿瘤负荷应作为次要终点。
  • 试验应包含从随机分组开始的终点:无事件生存和总生存。
  • 改编自STEEP 2.0的次要终点,从治愈意图手术开始定义,也可能适用。
  • 活检方案、影像学和病理淋巴结评估的规范化和标准化也至关重要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS: The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes-both pathologic and time-to-event survival end points-particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS: The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor-positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION: End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Litton JK, Regan MM, Pusztai L, et al. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023. PMID: 37433103. doi:10.1200/JCO.23.00435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。